Compare PLD & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLD | GSK |
|---|---|---|
| Founded | 1983 | 1715 |
| Country | United States | United Kingdom |
| Employees | 2802 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.9B | 96.1B |
| IPO Year | N/A | N/A |
| Metric | PLD | GSK |
|---|---|---|
| Price | $131.46 | $53.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 2 |
| Target Price | ★ $135.29 | N/A |
| AVG Volume (30 Days) | 2.7M | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.25% | 3.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.41 | $6.81 |
| Revenue Next Year | $5.88 | $4.74 |
| P/E Ratio | $39.25 | ★ $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.35 | $32.38 |
| 52 Week High | $143.95 | $61.70 |
| Indicator | PLD | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 37.71 |
| Support Level | $126.25 | $47.89 |
| Resistance Level | $134.94 | $60.37 |
| Average True Range (ATR) | 2.68 | 0.93 |
| MACD | -1.33 | -0.78 |
| Stochastic Oscillator | 12.40 | 1.31 |
Prologis was formed by the 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party assets under management. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.